MktsMarkets

Acrivon Therapeutics, Inc.
NASDAQ: ACRVKey statistics
ACRV News
Stories mentioning ACRV from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 15,166 | 14,746 | 13,648 | 16,182 | 15,414 | 18,630 | 18,864 | 15,025 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 19,902 | 20,116 | 19,687 | 22,649 | 21,662 | 24,954 | 25,140 | 21,437 |
| Operating Income (Loss) | (19,902) | (20,116) | (19,687) | (22,649) | (21,662) | (24,954) | (25,140) | (21,437) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (129.00) | (116.00) | (53.00) | (87.00) | (14.00) | (240.00) | 1.00 | (55.00) |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (19,042) | (18,985) | (18,234) | (21,006) | (19,680) | (22,831) | (22,441) | (18,798) |
| Earnings Per Share (Basic) | (0.49) | (0.49) | (0.47) | (0.55) | (0.51) | (0.68) | (0.59) | (0.52) |
| Earnings Per Share (Diluted) | (0.49) | (0.49) | (0.47) | (0.55) | (0.51) | (0.68) | (0.59) | (0.52) |
| Weighted Average Shares Outstanding (Basic) | 38,725 | 38,509 | 38,560 | 38,462 | 38,350 | 33,792 | 38,105 | 36,133 |
| Weighted Average Shares Outstanding (Diluted) | 38,725 | 38,509 | 38,560 | 38,462 | 38,350 | 33,792 | 38,105 | 36,133 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ACRV
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is a stock listed on the Nasdaq Stock Market under the ticker symbol ACRV. It last traded at $1.40 (Nov 19, 2026, 4:00 PM ET), down 10.3% on the day. That gives Acrivon Therapeutics a market capitalisation of $66.9M.
Over the past 52 weeks ACRV has traded between $1.27 and $3.56.
For the quarter ended Mar 31, 2026 it reported a net loss of $19.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$19.0M |
| Dec 31, 2025 | — | -$19.0M |
| Sep 30, 2025 | — | -$18.2M |
| Jun 30, 2025 | — | -$21.0M |
From Acrivon Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…